Dr. Hoffman-Censits

Jean Hoffman-Censits, MD

Contact Dr. Hoffman-Censits

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
  2. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States
  3. Recent developments in the treatment of advanced bladder cancer
  4. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy
  5. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  6. Recurrent renal cell carcinoma presenting as a solitary left ventricular mass
  7. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study
  8. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
  9. Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: Patient selection and special considerations
  10. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature
  11. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
  12. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies
  13. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer
  14. A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone for patientswithmetastatic castration-resistant prostate cancer progressing on abiraterone
  15. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  16. Combination immunotherapy in genitourinary malignancies
  17. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma
  18. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: Results of an investigator-initiated phase I-IIa clinical trial
  19. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
  20. Systemic chemotherapy for upper tract urothelial cancer